PHILADELPHIA — The American Association for Cancer Research (AACR) announces its collaboration with the clinical trial navigation system EmergingMed, to connect patients with clinical trials in connection to the Stand Up To Cancer (SU2C) broadcast which took place on Sept. 10, at 8 p.m. EDT & PDT / 7 p.m. CDT. The AACR-SU2C Clinical Trials Finder provides a resource for cancer patients and their loved ones to identify clinical trials that may be appropriate for their particular diagnosis, stage and treatment history.
“The AACR is thrilled to partner with EmergingMed, in conjunction with the landmark SU2C broadcast on Sept. 10, in order to help patients locate clinical trials for which they qualify,” said Margaret Foti, Ph.D., M.D. (h.c.), CEO of the American Association for Cancer Research. “SU2C’s mission is to provide effective treatments to patients quickly, and this partnership with EmergingMed helps realize that goal. Moreover, the AACR aims to educate the public about what clinical trials can offer, in order to help patients make educated decisions about their treatment options.”
The AACR is the sole scientific partner to SU2C. It is responsible for grants administration and management, and provides ongoing scientific oversight in conjunction with the SU2C Scientific Advisory Committee, led by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
The SU2C show, featuring cancer researchers as well as luminaries from film, TV, music, news and sports, was simulcast live on ABC, CBS, FOX, NBC, on more than a dozen other networks, and aired in more than 195 countries. Funds raised will fuel groundbreaking translational research around the world to accelerate the delivery of new therapies to patients.
The AACR’s Clinical Trials Navigators can be reached online at www.aacr/aacr-su2ctrialsfinder/ or toll free at 1-877-769-4829. Telephone hours are 8:30 a.m. to 6:00 p.m. ET, Monday through Friday.
The mission of EmergingMed is to create a coordinated, seamless connection between patients, clinical trials, and physicians at exactly the right time — when a person’s medical situation is perfectly aligned with a researcher’s effort to find new and better treatments. EmergingMed provides one-on-one patient navigation to clinical trials as well as business process solutions for trial sponsors, medical centers, investigators, and patient advocacy groups. Founded in 2000, EmergingMed’s patented system and method for matching patients to clinical trials currently supports clinical trial education and navigation services for over 50 organizations.
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Media Contact:
Michele Leiberman
michele.leiberman@aacr.org
